With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

Thyroid cancer incidence is increasing throughout the world. Although this appears to be due largely to enhanced detection of early thyroid cancers by the more generalised use of thyroid ultrasound ...

The US FDA’s approval is based on data from the ongoing Phase 2 PHAROS clinical trial (NCT03915951), an open-label, multicenter, single-arm study examining BRAFTOVI+MEKTOVI combination therapy in both ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

Researchers have discovered a signaling pathway between cytokines and BRAF that promotes tumor growth. The finding could provide a potential therapeutic target. The protein BRAF is a key player in the ...

Please provide your email address to receive an email when new articles are posted on . The triplet combination of vemurafenib/cobimetinib/atezolizumab showed ...

In patients with skin or lung cancer, drugs that inhibit BRAF (v-raf murine sarcoma viral oncogene homolog B) mutations increase the risk for uveitis dramatically compared with conventional ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...